To test whether EDB-FN is a therapy-predictive marker and if its expression correlates with changes in the invasive potential of breast cancer cells, the TGF-β-treated and drug-resistant MCF7 and MDA-MB-468 cells were treated with MK2206-HCl, a highly specific pan-AKT inhibitor proven to suppress PI3K/AKT signaling-induced tumor cell proliferation [42]. This evidence concerns the gene AKT1 and neoplasm.